Notably, antibody drug conjugates (ADC) targeting trophoblast cell surface antigen 2 (Trop-2), a transmembrane glycoprotein prevalent in NSCLC, are also gaining traction [43]. This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.